The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma

BackgroundBispecific antibodies (BsAbs) are widely used for the treatment of multiple myeloma (MM), but their long-term safety still provokes concerns.MethodsAdverse event (AE) data on teclistamab, talquetamab, and elranatamab between 1 August 2022 and 30 September 2024 were retrieved from the Food...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoling Zhou, Erdan Luo, Wei Chen, Yi Deng, Bo Wu, Xia Jiang, Kaili Zhang, Fan Lai
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Medicine
Subjects:
bispecific antibodies
AEs
MM
pharmacovigilance
FAERS
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1593405/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items